Phase II, multicenter, randomized, parallel-group study to evaluate the safety, tolerability, and pharmacokinetics of a second-generation VIR-7831 in non-hospitalized participants with mild coronavirus disease 2019 (COVID-19).
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: VIR BIOTECHNOLOGY INC.
- Phase: II
- Execution start: 21/06/2021
- End of execution: 28/02/2022
- PI: BERNARDINO ALCAZAR NAVARRETE